Pain management solution offered by Promex and Realeve honored with MedTech Breakthrough Award
In the realm of medical technology, the Pulsante device by Realeve is making waves as a potential game-changer in the treatment of central nervous system (CNS) disorders. This innovative device, which has received FDA Breakthrough Device designation and has been clinically proven in over 700 patients, offers even more precise treatment and improves patient outcomes.
Pulsante provides a more holistic treatment approach for chronic pain and neurological disorders, offering relief for patients suffering from conditions such as chronic migraine and neuropathic pain. It offers a drug-free, safe, and effective treatment option, reducing reliance on medications in managing chronic pain and neurological disorders.
The Pulsante system is a minimally invasive, battery-free, wireless compact SPG microstimulation implant. This design offers patients greater independence and improves quality of life by improving healthcare delivery. In studies of chronic cluster headaches, 75% of participants reported significant reduction in headache frequency and intensity using the Pulsante system over a four-week period.
Future iterations of the Pulsante technology may incorporate AI-based pain tracking and predictive analytics, further enhancing its precision and effectiveness.
Promex, a leader in microelectronic component assembly, process design, and packaging of medtech and biotech devices, worked with Realeve to manufacture a critical part of the Pulsante device, contributing to its success and recognition in the industry. The Pulsante RC-200 handheld device powers the implant and has the potential to treat a range of brain-related conditions.
The Pulsante technology may be used to treat other conditions linked to nerve dysfunction, such as sleep disorders and anxiety. Neurostimulation has shown promise in treating these conditions, and the Pulsante device, with its precision and non-invasive nature, could be a significant step forward in this field.
Dr. Peter Bonutti, founder and CEO of Realeve, has more than 30 years of experience and over 500 patents. His expertise and dedication have led to the development of this groundbreaking technology. Dr. Bonutti has been involved in other groundbreaking medtech projects, further solidifying his position as a leader in the field.
While the latest advancements in micro-neurostimulation for CNS disorders focus on ultraflexible, biocompatible neural interfaces and sophisticated computational models guiding stimulation protocols, direct recent detailed information on the Pulsante device by Realeve is not readily available. Further direct sources or company disclosures would be needed to provide specific recent advancements regarding Pulsante.
The MedTech Breakthrough Awards program, conducted by MedTech Breakthrough, recognises the top companies, technologies, and products in the global health and medical technology market. Realeve and the Pulsante device have been honoured with several awards, reflecting the industry's recognition of the potential of this innovative technology.
In conclusion, the Pulsante device by Realeve represents a significant step forward in the treatment of CNS disorders. While more information is needed to fully understand its latest advancements, its proven effectiveness in treating chronic pain and neurological disorders, combined with its potential to treat a range of brain-related conditions, makes it a technology to watch in the medical field.
The Pulsante device, developing under the guidance of Dr. Peter Bonutti and partnering with companies like Promex, is revolutionizing the field of digital health, specifically focusing on neurological disorders such as chronic migraine, neuropathic pain, sleep disorders, and anxiety. This device, utilizing AI-based pain tracking and predictive analytics, employs highly precise, non-invasive microstimulation to improve patient outcomes and quality of life. The technology, recognized by industry awards, continues to advance in the realm of science and health-and-wellness, showcasing the potential of technology to transform mental-health treatment and the management of medical-conditions.
